Peter M. Abadir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Peter M. Abadir has a total of 517 co-authors. Here are the top co-authors by number of shared publications:
Jeremy D. Walston
Division of Geriatric Medicine and Gerontology, Department of Medicine The Johns Hopkins University School of Medicine Baltimore Maryland USA
11 shared publicationsJeremy Walston
Division of Geriatric Medicine and Gerontology Johns Hopkins University School of Medicine Baltimore Maryland USA
11 shared publicationsAnne Le
Gigantest Baltimore Maryland USA
10 shared publications- Jeremy D. Walston
Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, USA
9 shared publications Cissy Zhang
Gigantest Baltimore Maryland USA
7 shared publications- Helmy M. Siragy
Department of Medicine, Division of Endocrinology and Metabolism University of Virginia Charlottesville Virginia USA
7 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in npj Aging
Review of artificial intelligence technologies for older adult health and wellbeing in NIA AITC Program
- 2 November 2026
- Published by Springer Nature in npj Aging
Open AccessReview of artificial intelligence technologies for older adult health and wellbeing in NIA AITC Program
- Open Access
- 10 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9)
Sustained Activation of CaMKII Promotes Skeletal Muscle Contractile Dysfunction in Aging
Sarcopenia, the age‐related loss of muscle strength and mass, contributes to adverse health outcomes in older adults. Exercise engages calcium (Ca 2+ )‐ and redox‐dependent signaling pathways that enhance muscle performance and adaptation, whereas aging disrupts Ca 2+ and redox homeostasis. CaMKII is a key transducer of both signals, raising the possibility that sustained CaMKII signaling becomes maladaptive with aging. Here, we show that CaMKII protein abundance is increased in aged mouse skeletal muscle and that sustained CaMKII activation in young muscle is sufficient to impair contractile function before substantial atrophy develops and, with prolonged activation, to promote progressive muscle loss. Sustained CaMKII activation also disrupted mitochondrial organization and shifted the young‐muscle transcriptome toward an aged profile characterized by inflammatory and stress‐response pathways. Inhibiting canonical NF‐κB signaling partially preserved contractile force during prolonged CaMKII activation without preserving muscle mass, and mediation analysis implicated heme/iron‐related transcriptional remodeling in the muscle‐mass‐independent decline in force. Conversely, expression of CN19o, a peptide inhibitor of CaMKII, in aged muscle improved contractile function and shifted the transcriptome away from an aging‐associated profile without inducing hypertrophy. Together, these findings identify sustained CaMKII signaling as a contributor to age‐associated muscle dysfunction and support a context‐dependent shift from adaptive CaMKII signaling in youth to maladaptive signaling in aging, consistent with antagonistic pleiotropy.
- 10 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9)
Open AccessSustained Activation of CaMKII Promotes Skeletal Muscle Contractile Dysfunction in Aging
Sarcopenia, the age‐related loss of muscle strength and mass, contributes to adverse health outcomes in older adults. Exercise engages calcium (Ca 2+ )‐ and redox‐dependent signaling pathways that enhance muscle performance and adaptation, whereas aging disrupts Ca 2+ and redox homeostasis. CaMKII is a key transducer of both signals, raising the possibility that sustained CaMKII signaling becomes maladaptive with aging. Here, we show that CaMKII protein abundance is increased in aged mouse skeletal muscle and that sustained CaMKII activation in young muscle is sufficient to impair contractile function before substantial atrophy develops and, with prolonged activation, to promote progressive muscle loss. Sustained CaMKII activation also disrupted mitochondrial organization and shifted the young‐muscle transcriptome toward an aged profile characterized by inflammatory and stress‐response pathways. Inhibiting canonical NF‐κB signaling partially preserved contractile force during prolonged CaMKII activation without preserving muscle mass, and mediation analysis implicated heme/iron‐related transcriptional remodeling in the muscle‐mass‐independent decline in force. Conversely, expression of CN19o, a peptide inhibitor of CaMKII, in aged muscle improved contractile function and shifted the transcriptome away from an aging‐associated profile without inducing hypertrophy. Together, these findings identify sustained CaMKII signaling as a contributor to age‐associated muscle dysfunction and support a context‐dependent shift from adaptive CaMKII signaling in youth to maladaptive signaling in aging, consistent with antagonistic pleiotropy.
- Open Access
- 30 August 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9) , e70686
Higher Frontal Cortex Angiotensin Type 2 Receptor‐Interacting Protein ( ATIP ) Levels Are Associated With a Lower Amyloid‐Beta Burden in Postmortem Brains of Older Adults With Alzheimer's Disease
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid‐β (Aβ) and tau accumulation. Dysregulation of the brain renin‐angiotensin system, particularly hyperactivation of the angiotensin II type‐1 receptor, contributes to AD pathogenesis. In contrast, activation of the angiotensin II type‐2 receptor (AT 2 R) has been linked to neuroprotection and reduced Aβ accumulation. However, the underlying mechanisms of AT 2 R‐related Aβ reduction and the role of AT 2 R‐interacting protein (ATIP), also known as AT 2 R‐binding protein, remain unclear. We aimed to explore the relationship between ATIP and Aβ and tau pathologies as well as brain AT 2 R protein levels in older adults with AD. Using TOMAHAQ, a method that enables precise examination of numerous peptides across various samples in a single mass spectrometry analysis, we identified a specific human tryptic peptide that enables ATIP quantification. We applied this method to postmortem frontal‐cortex samples to measure ATIP levels. Sixty individuals with AD were included, half of whom were users of angiotensin receptor blockers (ARBs). The ATIP peptide was quantifiable in 12 participants. Among these individuals, higher ATIP levels were associated with lower Aβ burden in the frontal‐cortex and across multiple brain regions. This association remained significant after adjustment for age and ARB use. In contrast, ATIP levels were not significantly associated with AT 2 R, which was quantified using TOMAHAQ. This suggests that the relationship between ATIP and Aβ burden may not depend on differences in AT 2 R abundance. Although causality cannot be established, these findings may suggest a potential protective role for ATIP in AD that warrants further investigation.
- 30 August 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9) , e70686
Open AccessHigher Frontal Cortex Angiotensin Type 2 Receptor‐Interacting Protein ( ATIP ) Levels Are Associated With a Lower Amyloid‐Beta Burden in Postmortem Brains of Older Adults With Alzheimer's Disease
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid‐β (Aβ) and tau accumulation. Dysregulation of the brain renin‐angiotensin system, particularly hyperactivation of the angiotensin II type‐1 receptor, contributes to AD pathogenesis. In contrast, activation of the angiotensin II type‐2 receptor (AT 2 R) has been linked to neuroprotection and reduced Aβ accumulation. However, the underlying mechanisms of AT 2 R‐related Aβ reduction and the role of AT 2 R‐interacting protein (ATIP), also known as AT 2 R‐binding protein, remain unclear. We aimed to explore the relationship between ATIP and Aβ and tau pathologies as well as brain AT 2 R protein levels in older adults with AD. Using TOMAHAQ, a method that enables precise examination of numerous peptides across various samples in a single mass spectrometry analysis, we identified a specific human tryptic peptide that enables ATIP quantification. We applied this method to postmortem frontal‐cortex samples to measure ATIP levels. Sixty individuals with AD were included, half of whom were users of angiotensin receptor blockers (ARBs). The ATIP peptide was quantifiable in 12 participants. Among these individuals, higher ATIP levels were associated with lower Aβ burden in the frontal‐cortex and across multiple brain regions. This association remained significant after adjustment for age and ARB use. In contrast, ATIP levels were not significantly associated with AT 2 R, which was quantified using TOMAHAQ. This suggests that the relationship between ATIP and Aβ burden may not depend on differences in AT 2 R abundance. Although causality cannot be established, these findings may suggest a potential protective role for ATIP in AD that warrants further investigation.
- 27 August 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (10) , 2854-2860
Artificial Intelligence and Health Care for Older Adults, a Future for All of Us
We are racing towards a time wherein the largest demographic of the population will be comprised of older adults and where it is now also possible to measure, monitor, and diagnose long term risk factors and provide effective and valuable preventative interventions. Thanks to the achievements of modern health care, we have reached a tipping point in the need for a robust geriatric workforce. Through the implementation of thoughtful, deliberate, and collaborative processes, Artificial Intelligence can play a significant role in preparing individuals in both mind and body for healthy aging. On May 1, 2025, the Johns Hopkins Artificial Intelligence and Technology Collaboratory (JH AITC) hosted a one‐day summit in Washington, DC, to explore the future and potential uses of Artificial Intelligence (AI) for older adults. Presenters and participants discussed the challenges facing the implementation of this technology into the U.S. health care system and the opportunities recent advances are affording in improving the quality of life for older adults.
- 27 August 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (10) , 2854-2860
Artificial Intelligence and Health Care for Older Adults, a Future for All of Us
We are racing towards a time wherein the largest demographic of the population will be comprised of older adults and where it is now also possible to measure, monitor, and diagnose long term risk factors and provide effective and valuable preventative interventions. Thanks to the achievements of modern health care, we have reached a tipping point in the need for a robust geriatric workforce. Through the implementation of thoughtful, deliberate, and collaborative processes, Artificial Intelligence can play a significant role in preparing individuals in both mind and body for healthy aging. On May 1, 2025, the Johns Hopkins Artificial Intelligence and Technology Collaboratory (JH AITC) hosted a one‐day summit in Washington, DC, to explore the future and potential uses of Artificial Intelligence (AI) for older adults. Presenters and participants discussed the challenges facing the implementation of this technology into the U.S. health care system and the opportunities recent advances are affording in improving the quality of life for older adults.
- Open Access
- 29 July 2026
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 9, e86148
The Ways in Which Stakeholders Make Decisions About AI and Novel Technologies for the Health Care of Older Adults: Qualitative Interview Study
Background: Artificial intelligence (AI) has the potential to improve health among older adults, yet how different stakeholders decide to develop, finance, and adopt AI innovations is not well understood. Objective: This study aimed to understand the decision-making of different stakeholders regarding AI and technologies for the health care of older adults. Methods: We conducted semistructured interviews with 15 older adults and care partners, 15 clinicians, 8 health system or insurance leaders, 5 investors, and 6 technology developers. Data were analyzed using thematic content analysis. Results: All stakeholders considered cost, value, and usability important in adopting AI health technologies but emphasized different aspects of each concept. Older adults and care partners prioritized out-of-pocket costs and ease of use, whereas payers emphasized disease prevalence and implementation feasibility. Developers and investors focused on profitability and scalability, resulting in tension with end users’ priorities. Participant suggestions included problem-driven design, greater stakeholder engagement, public-private partnerships, and educating older adults about AI. Conclusions: As with prior health-related technology innovations, aligning decisional priorities across stakeholders is critical to motivate impactful AI health technologies for older adults.
- 29 July 2026
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 9, e86148
Open AccessThe Ways in Which Stakeholders Make Decisions About AI and Novel Technologies for the Health Care of Older Adults: Qualitative Interview Study
Background: Artificial intelligence (AI) has the potential to improve health among older adults, yet how different stakeholders decide to develop, finance, and adopt AI innovations is not well understood. Objective: This study aimed to understand the decision-making of different stakeholders regarding AI and technologies for the health care of older adults. Methods: We conducted semistructured interviews with 15 older adults and care partners, 15 clinicians, 8 health system or insurance leaders, 5 investors, and 6 technology developers. Data were analyzed using thematic content analysis. Results: All stakeholders considered cost, value, and usability important in adopting AI health technologies but emphasized different aspects of each concept. Older adults and care partners prioritized out-of-pocket costs and ease of use, whereas payers emphasized disease prevalence and implementation feasibility. Developers and investors focused on profitability and scalability, resulting in tension with end users’ priorities. Participant suggestions included problem-driven design, greater stakeholder engagement, public-private partnerships, and educating older adults about AI. Conclusions: As with prior health-related technology innovations, aligning decisional priorities across stakeholders is critical to motivate impactful AI health technologies for older adults.
- Open Access
SureQuant IS-PRM Enables Cross-Species Targeted Quantification of Retinoid Metabolism and Signaling Proteins in the Heart
Retinoic acid signaling is critical for cardiac development and homeostasis. Dysregulation of all-trans retinoic acid metabolism contributes to vascular atherogenesis, restenosis, calcification, and heart failure. Therefore, assessment of proteins involved in retinoid metabolism and signaling has gained interest for identifying potential biomarkers and therapeutic targets in cardiovascular disease. However, quantifying these proteins remains challenging due to limitations of antibody-based methods. We developed a targeted proteomics approach using SureQuant internal standard-triggered parallel reaction monitoring mass spectrometry to profile these proteins. We designed a panel of 80 stable isotope-labeled (heavy) peptides representing proteins involved in retinoid signaling and metabolism, with sequences applicable to human samples and conserved across multiple species. Survey experiments using directed data-dependent acquisition on the Orbitrap Fusion Lumos mass spectrometer determined precursor and product ion masses for each heavy peptide, which were programmed into the SureQuant method for continuous monitoring. Upon detection of these heavy internal standards, the instrument transitions to a targeted PRM acquisition mode in which repeated high-resolution MS/MS spectra of both endogenous (light) and heavy peptides are acquired. Using this method, retinoid pathway-associated proteins were quantified to as low as 10 attomoles for selected targets across multiple tissues and developmental stages. Distinct tissue-specific retinoid metabolic networks were identified across lung, liver, retinal cell lines and cardiac tissues. Developmental profiling of mouse and rat hearts revealed remodeling of retinoid pathway proteins from embryonic to postnatal and adult stages, suggesting a functional transition from retinoid-driven cardiac development toward maintenance of retinoid homeostasis in the mature heart.
Open AccessSureQuant IS-PRM Enables Cross-Species Targeted Quantification of Retinoid Metabolism and Signaling Proteins in the Heart
Retinoic acid signaling is critical for cardiac development and homeostasis. Dysregulation of all-trans retinoic acid metabolism contributes to vascular atherogenesis, restenosis, calcification, and heart failure. Therefore, assessment of proteins involved in retinoid metabolism and signaling has gained interest for identifying potential biomarkers and therapeutic targets in cardiovascular disease. However, quantifying these proteins remains challenging due to limitations of antibody-based methods. We developed a targeted proteomics approach using SureQuant internal standard-triggered parallel reaction monitoring mass spectrometry to profile these proteins. We designed a panel of 80 stable isotope-labeled (heavy) peptides representing proteins involved in retinoid signaling and metabolism, with sequences applicable to human samples and conserved across multiple species. Survey experiments using directed data-dependent acquisition on the Orbitrap Fusion Lumos mass spectrometer determined precursor and product ion masses for each heavy peptide, which were programmed into the SureQuant method for continuous monitoring. Upon detection of these heavy internal standards, the instrument transitions to a targeted PRM acquisition mode in which repeated high-resolution MS/MS spectra of both endogenous (light) and heavy peptides are acquired. Using this method, retinoid pathway-associated proteins were quantified to as low as 10 attomoles for selected targets across multiple tissues and developmental stages. Distinct tissue-specific retinoid metabolic networks were identified across lung, liver, retinal cell lines and cardiac tissues. Developmental profiling of mouse and rat hearts revealed remodeling of retinoid pathway proteins from embryonic to postnatal and adult stages, suggesting a functional transition from retinoid-driven cardiac development toward maintenance of retinoid homeostasis in the mature heart.
- 21 July 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (10) , 2840-2853
Generative AI in the Care of Older Adults: A Position Statement From the American Geriatrics Society
Background: Generative artificial intelligence (GenAI), particularly large language models (LLMs), is being integrated into healthcare documentation, decision support, patient education, administrative workflows, and emerging agentic systems capable of initiating clinical and operational actions. While GenAI may reduce clinician burden and support person‐centered care, it also introduces risks such as misinformation, algorithmic bias, privacy harms, errors of omission, and automation over‐reliance. These risks may be amplified for older adults because core geriatrics care tasks, such as goals‐of‐care discussions, capacity‐sensitive consent, polypharmacy and deprescribing, and functional and cognitive assessment in the setting of multimorbidity, may be underrepresented in training data and are high‐stakes in practice. Methods: The American Geriatrics Society (AGS) convened an interdisciplinary working and writing group, reviewed relevant literature and reports, incorporated input from multiple AGS committees, and completed review and approval through AGS committee processes in March 2026. Results: This AGS position statement translates core geriatrics principles, person‐centered care, equity, shared decision‐making, and promoting independence into actionable recommendations for clinicians, health systems, developers, policymakers, older adults, and care partners. Recommendations address ethical use, clinical integration and oversight, transparency and documentation, privacy protections, governance across the AI lifecycle, including pre, during, and post‐deployment monitoring and accountability, and priority geriatrics use cases. Conclusion: GenAI should augment, not replace, clinical judgment and relational care. Responsible use in geriatrics requires transparency, clinician‐in‐the‐loop oversight, validation in older adult populations using age‐relevant outcomes, and governance safeguards to protect dignity, safety, and equity.
- 21 July 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (10) , 2840-2853
Generative AI in the Care of Older Adults: A Position Statement From the American Geriatrics Society
Background: Generative artificial intelligence (GenAI), particularly large language models (LLMs), is being integrated into healthcare documentation, decision support, patient education, administrative workflows, and emerging agentic systems capable of initiating clinical and operational actions. While GenAI may reduce clinician burden and support person‐centered care, it also introduces risks such as misinformation, algorithmic bias, privacy harms, errors of omission, and automation over‐reliance. These risks may be amplified for older adults because core geriatrics care tasks, such as goals‐of‐care discussions, capacity‐sensitive consent, polypharmacy and deprescribing, and functional and cognitive assessment in the setting of multimorbidity, may be underrepresented in training data and are high‐stakes in practice. Methods: The American Geriatrics Society (AGS) convened an interdisciplinary working and writing group, reviewed relevant literature and reports, incorporated input from multiple AGS committees, and completed review and approval through AGS committee processes in March 2026. Results: This AGS position statement translates core geriatrics principles, person‐centered care, equity, shared decision‐making, and promoting independence into actionable recommendations for clinicians, health systems, developers, policymakers, older adults, and care partners. Recommendations address ethical use, clinical integration and oversight, transparency and documentation, privacy protections, governance across the AI lifecycle, including pre, during, and post‐deployment monitoring and accountability, and priority geriatrics use cases. Conclusion: GenAI should augment, not replace, clinical judgment and relational care. Responsible use in geriatrics requires transparency, clinician‐in‐the‐loop oversight, validation in older adult populations using age‐relevant outcomes, and governance safeguards to protect dignity, safety, and equity.
- Open Access
- 13 July 2026
- Published by Elsevier in The Journal of Frailty & Aging
- Vol. 15, 100174
Welcome to the Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity (ICFSR 2026) in Washington, DC
- 13 July 2026
- Published by Elsevier in The Journal of Frailty & Aging
- Vol. 15, 100174
Open AccessWelcome to the Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity (ICFSR 2026) in Washington, DC
- Open Access
- 23 May 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (7) , 2143
Reply to: ‘Re: AI and Technology in Geriatrics: A New Chapter in JAGS’
- 23 May 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (7) , 2143
Open AccessReply to: ‘Re: AI and Technology in Geriatrics: A New Chapter in JAGS’
- Open Access
- 22 April 2026
- Published by Wiley in Aging Cell
- Vol. 25 (5) , e70498
Multi‐Omics Reveals Mechanisms of Metabolic Rejuvenation in Aged Mice and Pre‐Frail Older Men by Losartan
Aging is associated with significant alterations in systemic metabolism across species. We employed targeted metabolomics to investigate the effects of losartan, an angiotensin II receptor blocker, on the serum metabolome of aged mice and pre‐frail older men. Losartan treatment resulted in a shift in serum metabolome aging signature to a more youthful state. This rejuvenation effect appears to be contingent on the presence of functional angiotensin II receptors, with receptor knockout mice showing no rejuvenation effect with treatment. Additionally, we observed a similar rejuvenation effect of losartan in the cardiac proteome of aged mice, with the most pronounced changes occurring in proteins involved in oxidative phosphorylation. While our study did not encompass a full lifespan analysis, in alignment with previous reports of lifespan extension in other models, we noted a statistically significant improvement in survival among geriatric mice treated with losartan. In parallel, we analyzed serum metabolomics data from pre‐frail older men from a phase 2 randomized placebo‐controlled trial of losartan, which indicated a dose‐dependent metabolic rejuvenation effect. Correlation network analysis revealed divergent aging effects between species, with mice exhibiting broad decreases in metabolite concentrations and humans showing increases, particularly across lipid species. Principal component analysis further highlighted a global shift in metabolite levels, potentially linked to changes in lipoprotein metabolism, plasma volume, and amino acid metabolism with age. In summary, our results suggest that losartan can partially reverse age‐related metabolomic changes in both male mice and humans, with distinct species‐specific responses.
- 22 April 2026
- Published by Wiley in Aging Cell
- Vol. 25 (5) , e70498
Open AccessMulti‐Omics Reveals Mechanisms of Metabolic Rejuvenation in Aged Mice and Pre‐Frail Older Men by Losartan
Aging is associated with significant alterations in systemic metabolism across species. We employed targeted metabolomics to investigate the effects of losartan, an angiotensin II receptor blocker, on the serum metabolome of aged mice and pre‐frail older men. Losartan treatment resulted in a shift in serum metabolome aging signature to a more youthful state. This rejuvenation effect appears to be contingent on the presence of functional angiotensin II receptors, with receptor knockout mice showing no rejuvenation effect with treatment. Additionally, we observed a similar rejuvenation effect of losartan in the cardiac proteome of aged mice, with the most pronounced changes occurring in proteins involved in oxidative phosphorylation. While our study did not encompass a full lifespan analysis, in alignment with previous reports of lifespan extension in other models, we noted a statistically significant improvement in survival among geriatric mice treated with losartan. In parallel, we analyzed serum metabolomics data from pre‐frail older men from a phase 2 randomized placebo‐controlled trial of losartan, which indicated a dose‐dependent metabolic rejuvenation effect. Correlation network analysis revealed divergent aging effects between species, with mice exhibiting broad decreases in metabolite concentrations and humans showing increases, particularly across lipid species. Principal component analysis further highlighted a global shift in metabolite levels, potentially linked to changes in lipoprotein metabolism, plasma volume, and amino acid metabolism with age. In summary, our results suggest that losartan can partially reverse age‐related metabolomic changes in both male mice and humans, with distinct species‐specific responses.